Market Exclusivity "Give-Away" Gone In Bioterror Bill

Law360, New York (October 24, 2005, 12:00 AM EDT) -- The contentious “wildcard” provision for market exclusivity has been removed prior to a vote from an updated Biodefense bill on Capitol Hill, easing concerns of the generic drug industry while leaving intact other controversial language.

The so-called “BioShield II” bill has been approved by the Senate Committee on Health, Education, Labor and Pension (HELP). It was penned and introduced by Senator Richard Burr (R-NC) to prompt cooperation between the private and public sectors in drug development. Burr is chairman of the HELP Subcommittee on Bioterrorism and...
To view the full article, register now.